Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning

  • Mueller, Yvonne
  • Schrama, Thijs
  • Ruijten, Rik
  • Schreurs, Marco WJ
  • Grashof, Dwin
  • van de Werken, Harmen J. G.
  • Álvarez de la Sierra, Daniel
  • Hernández González, Manuel
  • Pujol Borrell, Ricardo
Applied immunology; Predictive markers; Viral infection, Immunologia aplicada; Marcadors predictius; Infecció viral, Inmunología aplicada; Marcadores predictivos; Infección viral, Quantitative or qualitative differences in immunity may drive clinical severity in COVID-19. Although longitudinal studies to record the course of immunological changes are ample, they do not necessarily predict clinical progression at the time of hospital admission. Here we show, by a machine learning approach using serum pro-inflammatory, anti-inflammatory and anti-viral cytokine and anti-SARS-CoV-2 antibody measurements as input data, that COVID-19 patients cluster into three distinct immune phenotype groups. These immune-types, determined by unsupervised hierarchical clustering that is agnostic to severity, predict clinical course. The identified immune-types do not associate with disease duration at hospital admittance, but rather reflect variations in the nature and kinetics of individual patient’s immune response. Thus, our work provides an immune-type based scheme to stratify COVID-19 patients at hospital admittance into high and low risk clinical categories with distinct cytokine and antibody profiles that may guide personalized therapy., This work was supported by Health Holland LSHM20056 grant (PDK), in part from the European Union’s Horizon 2020 research and innovation program under grant agreement No 779295 (PDK), in part supported by the Erasmus foundation (BJAR), grant PI20/00416 from the Instituto de Salud Carlos III (RPB) and the European Regional Development Fund (ERDF) (RPB).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Simple predictive models identify patients with COVID-19 pneumonia and poor prognosis

  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Labrador Horrillo, Moises|||0000-0003-3222-2380
  • Camps-Relats, Laura
  • González-Sans, Didac
  • Ventura-Cots, Meritxell|||0000-0001-9513-2855
  • Terrones-Peinador, María
  • Nuñez-Conde, Andrea
  • Martínez Gallo, Mónica|||0000-0002-7340-2161
  • Hernández, Manuel
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • González, Antonio|||0000-0002-2137-5835
  • Pujol-Borrell, Ricardo|||0000-0001-7833-675X
  • Martinez Valle, Fernando|||0000-0003-2673-2034
Identification of SARS-CoV-2-infected patients at high-risk of poor prognosis is crucial. We aimed to establish predictive models for COVID-19 pneumonia severity in hospitalized patients. Retrospective study of 430 patients admitted in Vall d'Hebron Hospital (Barcelona) between 03-12-2020 and 04-28-2020 due to COVID-19 pneumonia. Two models to identify the patients who required high-flow-oxygen-support were generated, one using baseline data and another with also follow-up analytical results. Calibration was performed by a 1000-bootstrap replication model. 249 were male, mean age 57.9 years. Overall, 135 (31.4%) required high-flow-oxygen-support. The baseline predictive model showed a ROC of 0.800 based on: SpO2/FiO2 (adjusted Hazard Ratio-aHR = 8), chest x-ray (aHR = 4), prior immunosuppressive therapy (aHR = 4), obesity (aHR = 2), IL-6 (aHR = 2), platelets (aHR = 0.5). The cut-off of 11 presented a specificity of 94.8%. The second model included changes on the analytical parameters: ferritin (aHR = 7.5 if ≥200ng/mL) and IL-6 (aHR = 18 if ≥64pg/mL) plus chest x-ray (aHR = 2) showing a ROC of 0.877. The cut-off of 12 exhibited a negative predictive value of 92%. SpO2/FiO2 and chest x-ray on admission or changes on inflammatory parameters as IL-6 and ferritin allow us early identification of COVID-19 patients at risk of high-flow-oxygen-support that may benefit from a more intensive disease management.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning

  • Mueller, Yvonne M.|||0000-0002-4654-7509
  • Schrama, Thijs J.|||0000-0002-6693-4725
  • Ruijten, Rik
  • Schreurs, Marco W. J.
  • Grashof, Dwin G. B.|||0000-0002-4169-9888
  • van de Werken, Harmen J. G.|||0000-0002-9794-1477
  • Lasinio, Giovanna Jona|||0000-0001-8912-5018
  • Álvarez-Sierra, Daniel|||0000-0001-8221-5117
  • Kiernan, Caoimhe H.
  • Castro Eiro, Melisa D.|||0000-0003-0780-8937
  • van Meurs, Marjan
  • Brouwers-Haspels, Inge|||0000-0003-4492-446X
  • Zhao, Manzhi
  • Li, Ling
  • de Wit, Harm
  • Ouzounis, Christos|||0000-0002-0086-8657
  • Wilmsen, Merel E. P.
  • Alofs, Tessa M.
  • Laport, Danique A.
  • van Wees, Tamara
  • Kraker, Geoffrey
  • Jaimes, Maria C.
  • Van Bockstael, Sebastiaan
  • Hernández-González, Manuel|||0000-0002-6932-5853
  • Rokx, Casper|||0000-0002-1904-6450
  • Rijnders, Bart J. A.|||0000-0003-3343-9610
  • Pujol-Borrell, Ricardo|||0000-0001-7833-675X
  • Katsikis, Peter D.|||0000-0001-7690-5218
Quantitative or qualitative differences in immunity may drive clinical severity in COVID-19. Although longitudinal studies to record the course of immunological changes are ample, they do not necessarily predict clinical progression at the time of hospital admission. Here we show, by a machine learning approach using serum pro-inflammatory, anti-inflammatory and anti-viral cytokine and anti-SARS-CoV-2 antibody measurements as input data, that COVID-19 patients cluster into three distinct immune phenotype groups. These immune-types, determined by unsupervised hierarchical clustering that is agnostic to severity, predict clinical course. The identified immune-types do not associate with disease duration at hospital admittance, but rather reflect variations in the nature and kinetics of individual patient's immune response. Thus, our work provides an immune-type based scheme to stratify COVID-19 patients at hospital admittance into high and low risk clinical categories with distinct cytokine and antibody profiles that may guide personalized therapy. Developing predictive methods to identify patients with high risk of severe COVID-19 disease is of crucial importance. Authors show here that by measuring anti-SARS-CoV-2 antibody and cytokine levels at the time of hospital admission and integrating the data by unsupervised hierarchical clustering/machine learning, it is possible to predict unfavourable outcome.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning

  • Mueller, Yvonne
  • Schrama, Thijs
  • Ruijten, Rik
  • Schreurs, Marco WJ
  • Grashof, Dwin
  • van de Werken, Harmen J. G.
  • Álvarez de la Sierra, Daniel
  • Hernández González, Manuel
  • Pujol Borrell, Ricardo
Applied immunology; Predictive markers; Viral infection, Immunologia aplicada; Marcadors predictius; Infecció viral, Inmunología aplicada; Marcadores predictivos; Infección viral, Quantitative or qualitative differences in immunity may drive clinical severity in COVID-19. Although longitudinal studies to record the course of immunological changes are ample, they do not necessarily predict clinical progression at the time of hospital admission. Here we show, by a machine learning approach using serum pro-inflammatory, anti-inflammatory and anti-viral cytokine and anti-SARS-CoV-2 antibody measurements as input data, that COVID-19 patients cluster into three distinct immune phenotype groups. These immune-types, determined by unsupervised hierarchical clustering that is agnostic to severity, predict clinical course. The identified immune-types do not associate with disease duration at hospital admittance, but rather reflect variations in the nature and kinetics of individual patient’s immune response. Thus, our work provides an immune-type based scheme to stratify COVID-19 patients at hospital admittance into high and low risk clinical categories with distinct cytokine and antibody profiles that may guide personalized therapy., This work was supported by Health Holland LSHM20056 grant (PDK), in part from the European Union’s Horizon 2020 research and innovation program under grant agreement No 779295 (PDK), in part supported by the Erasmus foundation (BJAR), grant PI20/00416 from the Instituto de Salud Carlos III (RPB) and the European Regional Development Fund (ERDF) (RPB).